Paul Dark, BSc, MD, PhD, FRCS, FRCEM, FFICM, originally studied physics and then medicine. Graduating from The Manchester Medical School, he went on to study clinical academic surgery, emergency medicine and critical care at the Universities of Glasgow and Manchester in the UK, and at the Catholic University of Leuven, Belgium. He was a MRC Clinical Training Fellow, completing his PhD supervised by Professor Rod Little at the UK’s MRC Trauma Unit. Dr. Dark was appointed to his current clinical academic post at the University of Manchester in 2003, carrying out clinical duties in Critical Care Medicine at Salford Royal NHS Foundation Trust, one of the largest services in the UK. He holds senior academic leadership positions at the University of Manchester focused on developing postgraduate learning in research and innovation in acute healthcare. In addition, he leads a programme of work funded by the National Institute of Health Research (NIHR) developing and assessing the diagnostic utility of emerging molecular technologies in the setting of sterile tissue injury and severe. Funded by Innovate UK (formerly Technology Strategy Board) Dr. Dark has led a programme of work developing novel technologies aimed at rapid point-of-care infection/sepsis diagnosis. He advises NICE on diagnostic technology appraisals in sepsis and he leads multi-centre pragmatic clinical trials aimed at developing an improved evidence base for the management    Paul Dark, BSc, MD, PhD, FRCS, FRCEM, FFICM, originally studied physics and then medicine. Graduating from The Manchester Medical School, he went on to study clinical academic surgery, emergency medicine and critical care at the Universities of Glasgow and Manchester in the UK, and at the Catholic University of Leuven, Belgium. He was a MRC Clinical Training Fellow, completing his PhD supervised by Professor Rod Little at the UK’s MRC Trauma Unit. Dr. Dark was appointed to his current clinical academic post at the University of Manchester in 2003, carrying out clinical duties in Critical Care Medicine at Salford Royal NHS Foundation Trust, one of the largest services in the UK. He holds senior academic leadership positions at the University of Manchester focused on developing postgraduate learning in research and innovation in acute healthcare. In addition, he leads a programme of work funded by the National Institute of Health Research (NIHR) developing and assessing the diagnostic utility of emerging molecular technologies in the setting of sterile tissue injury and severe. Funded by Innovate UK (formerly Technology Strategy Board) Dr. Dark has led a programme of work developing novel technologies aimed at rapid point-of-care infection/sepsis diagnosis. He advises NICE on diagnostic technology appraisals in sepsis and he leads multi-centre pragmatic clinical trials aimed at developing an improved evidence base for the management 

fermentation